Statins and Hypertension

 

 Buy Article Permissions and Reprints

ABSTRACT

Hypertension and dyslipidemia are frequently associated as risk factors for cardiovascular diseases. Statins are among the most potent drugs to correct hypercholesterolemia, and their use across a wide range of cardiovascular risk levels significantly reduced morbidity and mortality in large intervention trials. Aside from (or in addition to) reducing plasma cholesterol, statins also reduce blood pressure, another effect associated with cardiovascular risk reduction by other antihypertensive drugs. This review examines the proposition that a part of the statins’ beneficial effect in cardiovascular diseases may result from direct effects on blood pressure regulation, perhaps independent of lipid lowering. Potential molecular mechanisms are considered (e.g., “pleiotropic” effects on endothelial vasoactive mediators, oxidant stress, or inflammation), all of which may affect the central or peripheral control of blood pressure homeostasis, as well as modulate target organ damage. In particular, potential effects of statins on blood pressure and heart rate variability open new perspectives for a better tailoring of drug treatment in high-cardiovascular risk patients.

REFERENCES

• 1 Sever P S, Dahlof B, Poulter N R et al.. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.  Lancet. 2003;  361 1149-1158
  CrossrefPubMedGoogle Scholar
• 2 Lloyd-Jones D M, Evans J C, Larson M G et al.. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study.  Arch Intern Med. 1999;  159 2206-2212
  CrossrefPubMedGoogle Scholar
• 3 Pearson T A, Laurora I, Chu H et al.. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.  Arch Intern Med. 2000;  160 459-467
  CrossrefPubMedGoogle Scholar
• 4 Feron O, Dessy C, Moniotte S et al.. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase.  J Clin Invest. 1999;  103 897-905
  PubMedGoogle Scholar
• 5 Fielding C J, Bist A, Fielding P E. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers.  Proc Natl Acad Sci U S A. 1997;  94 3753-3758
  CrossrefPubMedGoogle Scholar
• 6 Nickenig G, Jung O, Strehlow K et al.. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression.  Am J Physiol. 1997;  272 H2701-H2707
  PubMedGoogle Scholar
• 7 Warnholtz A, Nickenig G, Schulz E et al.. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.  Circulation. 1999;  99 2027-2033
  CrossrefPubMedGoogle Scholar
• 8 Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function.  Exp Clin Endocrinol Diabetes. 2001;  109 S533-S547
  PubMedGoogle Scholar
• 9 Bakker S J, Ijzerman R G, Teerlink T, Westerhoff H V, Gans R O, Heine R J. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure?.  Atherosclerosis. 2000;  148 17-21
  CrossrefPubMedGoogle Scholar
• 10 Igarashi K, Tsuji M, Nishimura M et al.. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia.  J Clin Apheresis. 2004;  19 11-16
  CrossrefPubMedGoogle Scholar
• 11 Tamai O, Matsuoka H, Itabe H et al.. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.  Circulation. 1997;  95 76-82
  PubMedGoogle Scholar
• 12 Davignon J. The cardioprotective effects of statins.  Curr Atheroscler Rep. 2004;  6 27-35
  CrossrefPubMedGoogle Scholar
• 13 Wilson T W, Alonso-Galicia M, Roman R J. Effects of lipid-lowering agents in the Dahl salt-sensitive rat.  Hypertension. 1998;  31 225-231
  PubMedGoogle Scholar
• 14 Jiang J, Sun C W, Alonso-Galicia M et al.. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats.  Am J Hypertens. 1998;  11 1222-1231
  CrossrefPubMedGoogle Scholar
• 15 Jiang J, Roman R J. Lovastatin prevents development of hypertension in spontaneously hypertensive rats.  Hypertension. 1997;  30 968-974
  PubMedGoogle Scholar
• 16 Susic D, Varagic J, Ahn J et al.. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models.  J Am Coll Cardiol. 2003;  42 1091-1097
  CrossrefPubMedGoogle Scholar
• 17 Straznicky N E, Howes L G, Lam W et al.. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension.  Am J Cardiol. 1995;  75 582-586
  CrossrefPubMedGoogle Scholar
• 18 Abetel G, Poget P N, Bonnabry J P. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study.  Schweiz Med Wochenschr. 1998;  128 272-277
  PubMedGoogle Scholar
• 19 Glorioso N, Troffa C, Filigheddu F et al.. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.  Hypertension. 1999;  34 1281-1286
  PubMedGoogle Scholar
• 20 Sposito A C, Mansur A P, Coelho O R et al.. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).  Am J Cardiol. 1999;  83 1497-1499
  CrossrefPubMedGoogle Scholar
• 21 Borghi C, Prandin M G, Costa F V et al.. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia.  J Cardiovasc Pharmacol. 2000;  35 549-555
  CrossrefPubMedGoogle Scholar
• 22 Nazzaro P, Manzari M, Merlo M et al.. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects.  Hypertension. 1999;  33 719-725
  PubMedGoogle Scholar
• 23 Leibovitz E, Hazanov N, Zimlichman R et al.. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.  Am J Hypertens. 2001;  14 1096-1098
  CrossrefPubMedGoogle Scholar
• 24 Tonolo G, Melis M G, Formato M et al.. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.  Eur J Clin Invest. 2000;  30 980-987
  CrossrefPubMedGoogle Scholar
• 25 Prasad G V, Ahmed A, Nash M M et al.. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.  Kidney Int. 2003;  63 360-364
  CrossrefPubMedGoogle Scholar
• 26 Tsiara S, Elisaf M, Mikhailidis D P. Early vascular benefits of statin therapy.  Curr Med Res Opin. 2003;  19 540-556
  CrossrefPubMedGoogle Scholar
• 27 Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al.. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.  J Clin Invest. 1998;  101 2711-2719
  PubMedGoogle Scholar
• 28 Hernandez-Perera O, Perez-Sala D, Soria E et al.. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells.  Circ Res. 2000;  87 616-622
  PubMedGoogle Scholar
• 29 Ichiki T, Takeda K, Tokunou T et al.. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.  Arterioscler Thromb Vasc Biol. 2001;  21 1896-1901
  PubMedGoogle Scholar
• 30 Wassmann S, Laufs U, Baumer A T et al.. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.  Mol Pharmacol. 2001;  59 646-654
  PubMedGoogle Scholar
• 31 Wassmann S, Hilgers S, Laufs U et al.. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.  Arterioscler Thromb Vasc Biol. 2002;  22 1208-1212
  PubMedGoogle Scholar
• 32 Delbosc S, Morena M, Djouad F et al.. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.  J Cardiovasc Pharmacol. 2002;  40 611-617
  CrossrefPubMedGoogle Scholar
• 33 Laufs U, La Fata V, Plutzky J, Liao J K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.  Circulation. 1998;  97 1129-1135
  CrossrefPubMedGoogle Scholar
• 34 Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.  J Biol Chem. 1998;  273 24266-24271
  CrossrefPubMedGoogle Scholar
• 35 Kureishi Y, Luo Z, Shiojima I et al.. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.  Nat Med. 2000;  6 1004-1010
  CrossrefPubMedGoogle Scholar
• 36 Feron O, Dessy C, Desager J P et al.. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.  Circulation. 2001;  103 113-118
  PubMedGoogle Scholar
• 37 Pelat M, Dessy C, Massion P et al.. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.  Circulation. 2003;  107 2480-2486
  CrossrefPubMedGoogle Scholar
• 38 Drab M, Verkade P, Elger M et al.. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.  Science. 2001;  293 2449-2452
  CrossrefPubMedGoogle Scholar
• 39 Frank P G, Lee H, Park D S et al.. Genetic ablation of caveolin-1 confers protection against atherosclerosis.  Arterioscler Thromb Vasc Biol. 2004;  24 98-105
  PubMedGoogle Scholar
• 40 Bauersachs J, Galuppo P, Fraccarollo D et al.. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.  Circulation. 2001;  104 982-985
  PubMedGoogle Scholar
• 41 Takemoto M, Node K, Nakagami H et al.. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.  J Clin Invest. 2001;  108 1429-1437
  CrossrefPubMedGoogle Scholar
• 42 Lee T M, Chou T F, Tsai C H. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation.  J Cardiovasc Pharmacol. 2002;  40 868-874
  CrossrefPubMedGoogle Scholar
• 43 Kontopoulos A G, Athyros V G, Pehlivanidis A N et al.. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.  Curr Med Res Opin. 2003;  19 22-27
  CrossrefPubMedGoogle Scholar
• 44 Ferrier K E, Muhlmann M H, Baguet J P et al.. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.  J Am Coll Cardiol. 2002;  39 1020-1025
  CrossrefPubMedGoogle Scholar
• 45 Taylor A J, Kent S M, Flaherty P J et al.. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.  Circulation. 2002;  106 2055-2060
  CrossrefPubMedGoogle Scholar
• 46 Raison J, Rudnichi A, Safar M E. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.  J Hum Hypertens. 2002;  16 705-710
  CrossrefPubMedGoogle Scholar
• 47 Youssef F, Seifalian A M, Jagroop I A et al.. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).  Eur J Vasc Endovasc Surg. 2002;  23 358-364
  CrossrefPubMedGoogle Scholar
• 48 Parati G, Pomidossi G, Albini F et al.. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.  J Hypertens. 1987;  5 93-98
  CrossrefPubMedGoogle Scholar
• 49 Frattola A, Parati G, Cuspidi C et al.. Prognostic value of 24-hour blood pressure variability.  J Hypertens. 1993;  11 1133-1137
  CrossrefPubMedGoogle Scholar
• 50 Mancia G, Parati G, Hennig M et al.. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA).  J Hypertens. 2001;  19 1981-1989
  CrossrefPubMedGoogle Scholar
• 51 Sander D, Kukla C, Klingelhofer J et al.. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study.  Circulation. 2000;  102 1536-1541
  CrossrefPubMedGoogle Scholar
• 52 Parati G, Bilo G, Vettorello M et al.. Assessment of overall blood pressure variability and its different components.  Blood Press Monit. 2003;  8 155-159
  PubMedGoogle Scholar
• 53 Mussalo H, Vanninen E, Ikaheimo R et al.. Short-term blood pressure variability in renovascular hypertension and in severe and mild essential hypertension.  Clin Sci (Lond). 2003;  105 609-614
  PubMedGoogle Scholar
• 54 Frattola A, Parati G, Castiglioni P et al.. Lacidipine and blood pressure variability in diabetic hypertensive patients.  Hypertension. 2000;  36 622-628
  PubMedGoogle Scholar
• 55 Liu J G, Xu L P, Chu Z X et al.. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats.  J Hypertens. 2003;  21 1961-1967
  PubMedGoogle Scholar
• 56 Stauss H M, Nafz B, Mrowka R et al.. Blood pressure control in eNOS knock-out mice: comparison with other species under NO blockade.  Acta Physiol Scand. 2000;  168 155-160
  CrossrefPubMedGoogle Scholar
• 57 Riahi S, Christensen J H, Toft E et al.. HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction.  Pharmacol Res. 2002;  45 479-483
  CrossrefPubMedGoogle Scholar
• 58 Horwich T B, MacLellan W R, Fonarow G C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.  J Am Coll Cardiol. 2004;  43 642-648
  CrossrefPubMedGoogle Scholar
• 59 Pehlivanidis A N, Athyros V G, Demitriadis D S et al.. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.  Atherosclerosis. 2001;  157 463-469
  CrossrefPubMedGoogle Scholar
• 60 Welzig C M, Shin D G, Park H J et al.. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness.  Circulation. 2003;  108 2743-2746
  CrossrefPubMedGoogle Scholar
• 61 Pliquett R U, Cornish K G, Zucker I H. Statin therapy restores sympathovagal balance in experimental heart failure.  J Appl Physiol. 2003;  95 700-704
  PubMedGoogle Scholar
• 62 Pliquett R U, Cornish K G, Peuler J D et al.. Simvastatin normalizes autonomic neural control in experimental heart failure.  Circulation. 2003;  107 2493-2498
  CrossrefPubMedGoogle Scholar

Jean-Luc BalligandM.D. Ph.D. 

Unit of Pharmacology and Therapeutics, FATH 5349/Université Catholique de Louvain

53 Ave. Mounier, 1200 Brussels, Belgium